淋病治療薬の世界市場 2023-2027

淋病治療薬市場は2022-2027年に5億668万米ドル、予測期間中のCAGRは5.47%で成長すると予測されます。

当レポートでは、淋病治療薬市場の全体的な分析、市場規模・予測、動向、成長促進要因、課題、約25のベンダーを網羅したベンダー分析などを掲載しています。

現在の市場シナリオ、最新動向と促進要因、市場環境全体に関する最新分析を提供しています。市場は、淋病の有病率の上昇、淋病に関連する高リスクの合併症、新しい診断検査の使用の増加によって牽引されています。

本調査では、今後数年間の淋病治療薬市場成長を牽引する主な要因の1つとして、抗生物質耐性と闘うための政府イニシアチブの高まりを挙げています。また、淋病予防ワクチンの登場や迅速パートナー療法の採用拡大も、市場の大きな需要につながると思われます。

目次

第1章 エグゼクティブサマリー

• 市場概要

第2章 市場情勢

• 市場エコシステム

第3章 市場規模

• 市場の定義
• 市場セグメント分析
• 市場規模 2022
• 市場の見通し 2022-2027

第4章 市場規模実績

• 淋病治療薬の世界市場 2017-2021
• 流通チャネル別セグメント分析 2017-2021
• 療法別セグメント分析 2017-2021
• 地域別セグメント分析 2017-2021
• 国別セグメント分析 2017-2021

第5章 ファイブフォース分析

• ファイブフォースの要約
• 買い手の交渉力
• 供給企業の交渉力
• 新規参入業者の脅威
• 代替品の脅威
• 競争の脅威
• 市況

第6章 市場セグメンテーション：流通チャネル別

• 市場セグメント
• 比較：流通チャネル別
• 病院薬局：市場規模と予測 2022-2027
• 小売薬局：市場規模と予測 2022-2027
• オンライン薬局：市場規模と予測 2022-2027
• 市場機会：流通チャネル別

第7章 市場セグメンテーション：療法別

• 市場セグメント
• 比較：療法別
• 単独療法：市場規模と予測 2022-2027
• 併用療法：市場規模と予測 2022-2027
• 市場機会：療法別

第8章 顧客情勢

• 顧客情勢の概要

第9章 地域別情勢

• 地域別セグメンテーション
• 地域別比較
• 北米：市場規模と予測 2022-2027
• 欧州：市場規模と予測 2022-2027
• アジア：市場規模と予測 2022-2027
• 世界のその他の地域：市場規模と予測 2022-2027
• 米国：市場規模と予測 2022-2027
• ドイツ：市場規模と予測 2022-2027
• 中国：市場規模と予測 2022-2027
• 英国：市場規模と予測 2022-2027
• 日本：市場規模と予測 2022-2027
• 市場機会：地域情勢別

第10章 促進要因、課題、および動向

• 市場促進要因
• 市場の課題
• 促進要因と課題の影響
• 市場動向

第11章 ベンダー情勢

• 概要
• ベンダー情勢
• 混乱の状況
• 業界のリスク

第12章 ベンダー分析

• 対象ベンダー
• ベンダーの市場ポジショニング
• Apotex Inc.
• Aurobindo Pharma Ltd.
• Bristol Myers Squibb Co.
• Cipla Ltd.
• Debiopharm International SA
• Entasis Therapeutics
• F. Hoffmann La Roche Ltd.
• GlaxoSmithKline Plc
• Hikma Pharmaceuticals Plc
• Lupin Ltd.
• Mayne Pharma Group Ltd.
• Pfizer Inc.
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• Therapyx Inc.

第13章 付録

Exhibits:

• Exhibits1: Executive Summary - Chart on Market Overview
• Exhibits2: Executive Summary - Data Table on Market Overview
• Exhibits3: Executive Summary - Chart on Global Market Characteristics
• Exhibits4: Executive Summary - Chart on Market By Geographical Landscape
• Exhibits5: Executive Summary - Chart on Market Segmentation by Distribution Channel
• Exhibits6: Executive Summary - Chart on Market Segmentation by Therapy
• Exhibits7: Executive Summary - Chart on Incremental Growth
• Exhibits8: Executive Summary - Data Table on Incremental Growth
• Exhibits9: Executive Summary - Chart on Vendor Market Positioning
• Exhibits10: Parent market
• Exhibits11: Market Characteristics
• Exhibits12: Offerings of vendors included in the market definition
• Exhibits13: Market segments
• Exhibits14: Chart on Global - Market size and forecast 2022-2027 ($ million)
• Exhibits15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
• Exhibits16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
• Exhibits17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
• Exhibits18: Historic Market Size - Data Table on global gonorrhea therapeutics market 2017 - 2021 ($ million)
• Exhibits19: Historic Market Size - Distribution Channel Segment 2017 - 2021 ($ million)
• Exhibits20: Historic Market Size - Therapy Segment 2017 - 2021 ($ million)
• Exhibits21: Historic Market Size - Geography Segment 2017 - 2021 ($ million)
• Exhibits22: Historic Market Size - Country Segment 2017 - 2021 ($ million)
• Exhibits23: Five forces analysis - Comparison between 2022 and 2027
• Exhibits24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027
• Exhibits25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027
• Exhibits26: Threat of new entrants - Impact of key factors in 2022 and 2027
• Exhibits27: Threat of substitutes - Impact of key factors in 2022 and 2027
• Exhibits28: Threat of rivalry - Impact of key factors in 2022 and 2027
• Exhibits29: Chart on Market condition - Five forces 2022 and 2027
• Exhibits30: Chart on Distribution Channel - Market share 2022-2027 (%)
• Exhibits31: Data Table on Distribution Channel - Market share 2022-2027 (%)
• Exhibits32: Chart on Comparison by Distribution Channel
• Exhibits33: Data Table on Comparison by Distribution Channel
• Exhibits34: Chart on Hospital pharmacies - Market size and forecast 2022-2027 ($ million)
• Exhibits35: Data Table on Hospital pharmacies - Market size and forecast 2022-2027 ($ million)
• Exhibits36: Chart on Hospital pharmacies - Year-over-year growth 2022-2027 (%)
• Exhibits37: Data Table on Hospital pharmacies - Year-over-year growth 2022-2027 (%)
• Exhibits38: Chart on Retail pharmacies - Market size and forecast 2022-2027 ($ million)
• Exhibits39: Data Table on Retail pharmacies - Market size and forecast 2022-2027 ($ million)
• Exhibits40: Chart on Retail pharmacies - Year-over-year growth 2022-2027 (%)
• Exhibits41: Data Table on Retail pharmacies - Year-over-year growth 2022-2027 (%)
• Exhibits42: Chart on Online pharmacies - Market size and forecast 2022-2027 ($ million)
• Exhibits43: Data Table on Online pharmacies - Market size and forecast 2022-2027 ($ million)
• Exhibits44: Chart on Online pharmacies - Year-over-year growth 2022-2027 (%)
• Exhibits45: Data Table on Online pharmacies - Year-over-year growth 2022-2027 (%)
• Exhibits46: Market opportunity by Distribution Channel ($ million)
• Exhibits47: Data Table on Market opportunity by Distribution Channel ($ million)
• Exhibits48: Chart on Therapy - Market share 2022-2027 (%)
• Exhibits49: Data Table on Therapy - Market share 2022-2027 (%)
• Exhibits50: Chart on Comparison by Therapy
• Exhibits51: Data Table on Comparison by Therapy
• Exhibits52: Chart on Monotherapy - Market size and forecast 2022-2027 ($ million)
• Exhibits53: Data Table on Monotherapy - Market size and forecast 2022-2027 ($ million)
• Exhibits54: Chart on Monotherapy - Year-over-year growth 2022-2027 (%)
• Exhibits55: Data Table on Monotherapy - Year-over-year growth 2022-2027 (%)
• Exhibits56: Chart on Combination therapy - Market size and forecast 2022-2027 ($ million)
• Exhibits57: Data Table on Combination therapy - Market size and forecast 2022-2027 ($ million)
• Exhibits58: Chart on Combination therapy - Year-over-year growth 2022-2027 (%)
• Exhibits59: Data Table on Combination therapy - Year-over-year growth 2022-2027 (%)
• Exhibits60: Market opportunity by Therapy ($ million)
• Exhibits61: Data Table on Market opportunity by Therapy ($ million)
• Exhibits62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• Exhibits63: Chart on Market share By Geographical Landscape 2022-2027 (%)
• Exhibits64: Data Table on Market share By Geographical Landscape 2022-2027 (%)
• Exhibits65: Chart on Geographic comparison
• Exhibits66: Data Table on Geographic comparison
• Exhibits67: Chart on North America - Market size and forecast 2022-2027 ($ million)
• Exhibits68: Data Table on North America - Market size and forecast 2022-2027 ($ million)
• Exhibits69: Chart on North America - Year-over-year growth 2022-2027 (%)
• Exhibits70: Data Table on North America - Year-over-year growth 2022-2027 (%)
• Exhibits71: Chart on Europe - Market size and forecast 2022-2027 ($ million)
• Exhibits72: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
• Exhibits73: Chart on Europe - Year-over-year growth 2022-2027 (%)
• Exhibits74: Data Table on Europe - Year-over-year growth 2022-2027 (%)
• Exhibits75: Chart on Asia - Market size and forecast 2022-2027 ($ million)
• Exhibits76: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
• Exhibits77: Chart on Asia - Year-over-year growth 2022-2027 (%)
• Exhibits78: Data Table on Asia - Year-over-year growth 2022-2027 (%)
• Exhibits79: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
• Exhibits80: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
• Exhibits81: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
• Exhibits82: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
• Exhibits83: Chart on US - Market size and forecast 2022-2027 ($ million)
• Exhibits84: Data Table on US - Market size and forecast 2022-2027 ($ million)
• Exhibits85: Chart on US - Year-over-year growth 2022-2027 (%)
• Exhibits86: Data Table on US - Year-over-year growth 2022-2027 (%)
• Exhibits87: Chart on Germany - Market size and forecast 2022-2027 ($ million)
• Exhibits88: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
• Exhibits89: Chart on Germany - Year-over-year growth 2022-2027 (%)
• Exhibits90: Data Table on Germany - Year-over-year growth 2022-2027 (%)
• Exhibits91: Chart on China - Market size and forecast 2022-2027 ($ million)
• Exhibits92: Data Table on China - Market size and forecast 2022-2027 ($ million)
• Exhibits93: Chart on China - Year-over-year growth 2022-2027 (%)
• Exhibits94: Data Table on China - Year-over-year growth 2022-2027 (%)
• Exhibits95: Chart on UK - Market size and forecast 2022-2027 ($ million)
• Exhibits96: Data Table on UK - Market size and forecast 2022-2027 ($ million)
• Exhibits97: Chart on UK - Year-over-year growth 2022-2027 (%)
• Exhibits98: Data Table on UK - Year-over-year growth 2022-2027 (%)
• Exhibits99: Chart on Japan - Market size and forecast 2022-2027 ($ million)
• Exhibits100: Data Table on Japan - Market size and forecast 2022-2027 ($ million)
• Exhibits101: Chart on Japan - Year-over-year growth 2022-2027 (%)
• Exhibits102: Data Table on Japan - Year-over-year growth 2022-2027 (%)
• Exhibits103: Market opportunity By Geographical Landscape ($ million)
• Exhibits104: Data Tables on Market opportunity By Geographical Landscape ($ million)
• Exhibits105: Impact of drivers and challenges in 2022 and 2027
• Exhibits106: Overview on Criticality of inputs and Factors of differentiation
• Exhibits107: Overview on factors of disruption
• Exhibits108: Impact of key risks on business
• Exhibits109: Vendors covered
• Exhibits110: Matrix on vendor position and classification
• Exhibits111: Apotex Inc. - Overview
• Exhibits112: Apotex Inc. - Product / Service
• Exhibits113: Apotex Inc. - Key offerings
• Exhibits114: Aurobindo Pharma Ltd. - Overview
• Exhibits115: Aurobindo Pharma Ltd. - Product / Service
• Exhibits116: Aurobindo Pharma Ltd. - Key offerings
• Exhibits117: Bristol Myers Squibb Co. - Overview
• Exhibits118: Bristol Myers Squibb Co. - Product / Service
• Exhibits119: Bristol Myers Squibb Co. - Key news
• Exhibits120: Bristol Myers Squibb Co. - Key offerings
• Exhibits121: Cipla Ltd. - Overview
• Exhibits122: Cipla Ltd. - Business segments
• Exhibits123: Cipla Ltd. - Key news
• Exhibits124: Cipla Ltd. - Key offerings
• Exhibits125: Cipla Ltd. - Segment focus
• Exhibits126: Debiopharm International SA - Overview
• Exhibits127: Debiopharm International SA - Product / Service
• Exhibits128: Debiopharm International SA - Key news
• Exhibits129: Debiopharm International SA - Key offerings
• Exhibits130: Entasis Therapeutics - Overview
• Exhibits131: Entasis Therapeutics - Product / Service
• Exhibits132: Entasis Therapeutics - Key offerings
• Exhibits133: F. Hoffmann La Roche Ltd. - Overview
• Exhibits134: F. Hoffmann La Roche Ltd. - Business segments
• Exhibits135: F. Hoffmann La Roche Ltd. - Key news
• Exhibits136: F. Hoffmann La Roche Ltd. - Key offerings
• Exhibits137: F. Hoffmann La Roche Ltd. - Segment focus
• Exhibits138: GlaxoSmithKline Plc - Overview
• Exhibits139: GlaxoSmithKline Plc - Business segments
• Exhibits140: GlaxoSmithKline Plc - Key news
• Exhibits141: GlaxoSmithKline Plc - Key offerings
• Exhibits142: GlaxoSmithKline Plc - Segment focus
• Exhibits143: Hikma Pharmaceuticals Plc - Overview
• Exhibits144: Hikma Pharmaceuticals Plc - Business segments
• Exhibits145: Hikma Pharmaceuticals Plc - Key offerings
• Exhibits146: Hikma Pharmaceuticals Plc - Segment focus
• Exhibits147: Lupin Ltd. - Overview
• Exhibits148: Lupin Ltd. - Product / Service
• Exhibits149: Lupin Ltd. - Key news
• Exhibits150: Lupin Ltd. - Key offerings
• Exhibits151: Mayne Pharma Group Ltd. - Overview
• Exhibits152: Mayne Pharma Group Ltd. - Business segments
• Exhibits153: Mayne Pharma Group Ltd. - Key news
• Exhibits154: Mayne Pharma Group Ltd. - Key offerings
• Exhibits155: Mayne Pharma Group Ltd. - Segment focus
• Exhibits156: Pfizer Inc. - Overview
• Exhibits157: Pfizer Inc. - Product / Service
• Exhibits158: Pfizer Inc. - Key news
• Exhibits159: Pfizer Inc. - Key offerings
• Exhibits160: Sun Pharmaceutical Industries Ltd. - Overview
• Exhibits161: Sun Pharmaceutical Industries Ltd. - Product / Service
• Exhibits162: Sun Pharmaceutical Industries Ltd. - Key offerings
• Exhibits163: Teva Pharmaceutical Industries Ltd. - Overview
• Exhibits164: Teva Pharmaceutical Industries Ltd. - Business segments
• Exhibits165: Teva Pharmaceutical Industries Ltd. - Key news
• Exhibits166: Teva Pharmaceutical Industries Ltd. - Key offerings
• Exhibits167: Teva Pharmaceutical Industries Ltd. - Segment focus
• Exhibits168: Therapyx Inc. - Overview
• Exhibits169: Therapyx Inc. - Product / Service
• Exhibits170: Therapyx Inc. - Key offerings
• Exhibits171: Inclusions checklist
• Exhibits172: Exclusions checklist
• Exhibits173: Currency conversion rates for US$
• Exhibits174: Research methodology
• Exhibits175: Validation techniques employed for market sizing
• Exhibits176: Information sources
• Exhibits177: List of abbreviations

The gonorrhea therapeutics market is forecasted to grow by USD 506.68 mn during 2022-2027, accelerating at a CAGR of 5.47% during the forecast period. The report on the gonorrhea therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rising prevalence of gonorrhea, high-risk complications associated with gonorrhea, and growing use of new diagnostic tests.

Technavio's gonorrhea therapeutics market is segmented as below:

By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

By Therapy

• Monotherapy
• Combination therapy

By Geographical Landscape

• North America
• Europe
• Asia
• Rest of World (ROW)

This study identifies the rising government initiatives to combat antibiotic resistance as one of the prime reasons driving the gonorrhea therapeutics market growth during the next few years. Also, advent of vaccines for prevention of gonorrhea and increased adoption of expedited partner therapy will lead to sizable demand in the market.

The report on the gonorrhea therapeutics market covers the following areas:

• Gonorrhea therapeutics market sizing
• Gonorrhea therapeutics market forecast
• Gonorrhea therapeutics market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading gonorrhea therapeutics market vendors that include Apotex Inc., Aurobindo Pharma Ltd., Bristol Myers Squibb Co., Cipla Ltd., Debiopharm International SA, F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Hikma Pharmaceuticals Plc, Lupin Ltd., Mayne Pharma Group Ltd., Pfizer Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Therapyx Inc., and Entasis Therapeutics. Also, the gonorrhea therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Table of Contents

1 Executive Summary

• 1.1 Market overview
• Exhibit 01: Executive Summary - Chart on Market Overview
• Exhibit 02: Executive Summary - Data Table on Market Overview
• Exhibit 03: Executive Summary - Chart on Global Market Characteristics
• Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
• Exhibit 05: Executive Summary - Chart on Market Segmentation by Distribution Channel
• Exhibit 06: Executive Summary - Chart on Market Segmentation by Therapy
• Exhibit 07: Executive Summary - Chart on Incremental Growth
• Exhibit 08: Executive Summary - Data Table on Incremental Growth
• Exhibit 09: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape

• 2.1 Market ecosystem
• Exhibit 10: Parent market
• Exhibit 11: Market Characteristics

3 Market Sizing

• 3.1 Market definition
• Exhibit 12: Offerings of vendors included in the market definition
• 3.2 Market segment analysis
• Exhibit 13: Market segments
• 3.3 Market size 2022
• 3.4 Market outlook: Forecast for 2022-2027
• Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
• Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
• Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
• Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

4 Historic Market Size

• 4.1 Global gonorrhea therapeutics market 2017 - 2021
• Exhibit 18: Historic Market Size - Data Table on global gonorrhea therapeutics market 2017 - 2021 ($ million)
• 4.2 Distribution Channel Segment Analysis 2017 - 2021
• Exhibit 19: Historic Market Size - Distribution Channel Segment 2017 - 2021 ($ million)
• 4.3 Therapy Segment Analysis 2017 - 2021
• Exhibit 20: Historic Market Size - Therapy Segment 2017 - 2021 ($ million)
• 4.4 Geography Segment Analysis 2017 - 2021
• Exhibit 21: Historic Market Size - Geography Segment 2017 - 2021 ($ million)
• 4.5 Country Segment Analysis 2017 - 2021
• Exhibit 22: Historic Market Size - Country Segment 2017 - 2021 ($ million)

5 Five Forces Analysis

• 5.1 Five forces summary
• Exhibit 23: Five forces analysis - Comparison between 2022 and 2027
• 5.2 Bargaining power of buyers
• Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027
• 5.3 Bargaining power of suppliers
• Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027
• 5.4 Threat of new entrants
• Exhibit 26: Threat of new entrants - Impact of key factors in 2022 and 2027
• 5.5 Threat of substitutes
• Exhibit 27: Threat of substitutes - Impact of key factors in 2022 and 2027
• 5.6 Threat of rivalry
• Exhibit 28: Threat of rivalry - Impact of key factors in 2022 and 2027
• 5.7 Market condition
• Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

6 Market Segmentation by Distribution Channel

• 6.1 Market segments
• Exhibit 30: Chart on Distribution Channel - Market share 2022-2027 (%)
• Exhibit 31: Data Table on Distribution Channel - Market share 2022-2027 (%)
• 6.2 Comparison by Distribution Channel
• Exhibit 32: Chart on Comparison by Distribution Channel
• Exhibit 33: Data Table on Comparison by Distribution Channel
• 6.3 Hospital pharmacies - Market size and forecast 2022-2027
• Exhibit 34: Chart on Hospital pharmacies - Market size and forecast 2022-2027 ($ million)
• Exhibit 35: Data Table on Hospital pharmacies - Market size and forecast 2022-2027 ($ million)
• Exhibit 36: Chart on Hospital pharmacies - Year-over-year growth 2022-2027 (%)
• Exhibit 37: Data Table on Hospital pharmacies - Year-over-year growth 2022-2027 (%)
• 6.4 Retail pharmacies - Market size and forecast 2022-2027
• Exhibit 38: Chart on Retail pharmacies - Market size and forecast 2022-2027 ($ million)
• Exhibit 39: Data Table on Retail pharmacies - Market size and forecast 2022-2027 ($ million)
• Exhibit 40: Chart on Retail pharmacies - Year-over-year growth 2022-2027 (%)
• Exhibit 41: Data Table on Retail pharmacies - Year-over-year growth 2022-2027 (%)
• 6.5 Online pharmacies - Market size and forecast 2022-2027
• Exhibit 42: Chart on Online pharmacies - Market size and forecast 2022-2027 ($ million)
• Exhibit 43: Data Table on Online pharmacies - Market size and forecast 2022-2027 ($ million)
• Exhibit 44: Chart on Online pharmacies - Year-over-year growth 2022-2027 (%)
• Exhibit 45: Data Table on Online pharmacies - Year-over-year growth 2022-2027 (%)
• 6.6 Market opportunity by Distribution Channel
• Exhibit 46: Market opportunity by Distribution Channel ($ million)
• Exhibit 47: Data Table on Market opportunity by Distribution Channel ($ million)

7 Market Segmentation by Therapy

• 7.1 Market segments
• Exhibit 48: Chart on Therapy - Market share 2022-2027 (%)
• Exhibit 49: Data Table on Therapy - Market share 2022-2027 (%)
• 7.2 Comparison by Therapy
• Exhibit 50: Chart on Comparison by Therapy
• Exhibit 51: Data Table on Comparison by Therapy
• 7.3 Monotherapy - Market size and forecast 2022-2027
• Exhibit 52: Chart on Monotherapy - Market size and forecast 2022-2027 ($ million)
• Exhibit 53: Data Table on Monotherapy - Market size and forecast 2022-2027 ($ million)
• Exhibit 54: Chart on Monotherapy - Year-over-year growth 2022-2027 (%)
• Exhibit 55: Data Table on Monotherapy - Year-over-year growth 2022-2027 (%)
• 7.4 Combination therapy - Market size and forecast 2022-2027
• Exhibit 56: Chart on Combination therapy - Market size and forecast 2022-2027 ($ million)
• Exhibit 57: Data Table on Combination therapy - Market size and forecast 2022-2027 ($ million)
• Exhibit 58: Chart on Combination therapy - Year-over-year growth 2022-2027 (%)
• Exhibit 59: Data Table on Combination therapy - Year-over-year growth 2022-2027 (%)
• 7.5 Market opportunity by Therapy
• Exhibit 60: Market opportunity by Therapy ($ million)
• Exhibit 61: Data Table on Market opportunity by Therapy ($ million)

8 Customer Landscape

• 8.1 Customer landscape overview
• Exhibit 62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

• 9.1 Geographic segmentation
• Exhibit 63: Chart on Market share By Geographical Landscape 2022-2027 (%)
• Exhibit 64: Data Table on Market share By Geographical Landscape 2022-2027 (%)
• 9.2 Geographic comparison
• Exhibit 65: Chart on Geographic comparison
• Exhibit 66: Data Table on Geographic comparison
• 9.3 North America - Market size and forecast 2022-2027
• Exhibit 67: Chart on North America - Market size and forecast 2022-2027 ($ million)
• Exhibit 68: Data Table on North America - Market size and forecast 2022-2027 ($ million)
• Exhibit 69: Chart on North America - Year-over-year growth 2022-2027 (%)
• Exhibit 70: Data Table on North America - Year-over-year growth 2022-2027 (%)
• 9.4 Europe - Market size and forecast 2022-2027
• Exhibit 71: Chart on Europe - Market size and forecast 2022-2027 ($ million)
• Exhibit 72: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
• Exhibit 73: Chart on Europe - Year-over-year growth 2022-2027 (%)
• Exhibit 74: Data Table on Europe - Year-over-year growth 2022-2027 (%)
• 9.5 Asia - Market size and forecast 2022-2027
• Exhibit 75: Chart on Asia - Market size and forecast 2022-2027 ($ million)
• Exhibit 76: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
• Exhibit 77: Chart on Asia - Year-over-year growth 2022-2027 (%)
• Exhibit 78: Data Table on Asia - Year-over-year growth 2022-2027 (%)
• 9.6 Rest of World (ROW) - Market size and forecast 2022-2027
• Exhibit 79: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
• Exhibit 80: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
• Exhibit 81: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
• Exhibit 82: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
• 9.7 US - Market size and forecast 2022-2027
• Exhibit 83: Chart on US - Market size and forecast 2022-2027 ($ million)
• Exhibit 84: Data Table on US - Market size and forecast 2022-2027 ($ million)
• Exhibit 85: Chart on US - Year-over-year growth 2022-2027 (%)
• Exhibit 86: Data Table on US - Year-over-year growth 2022-2027 (%)
• 9.8 Germany - Market size and forecast 2022-2027
• Exhibit 87: Chart on Germany - Market size and forecast 2022-2027 ($ million)
• Exhibit 88: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
• Exhibit 89: Chart on Germany - Year-over-year growth 2022-2027 (%)
• Exhibit 90: Data Table on Germany - Year-over-year growth 2022-2027 (%)
• 9.9 China - Market size and forecast 2022-2027
• Exhibit 91: Chart on China - Market size and forecast 2022-2027 ($ million)
• Exhibit 92: Data Table on China - Market size and forecast 2022-2027 ($ million)
• Exhibit 93: Chart on China - Year-over-year growth 2022-2027 (%)
• Exhibit 94: Data Table on China - Year-over-year growth 2022-2027 (%)
• 9.10 UK - Market size and forecast 2022-2027
• Exhibit 95: Chart on UK - Market size and forecast 2022-2027 ($ million)
• Exhibit 96: Data Table on UK - Market size and forecast 2022-2027 ($ million)
• Exhibit 97: Chart on UK - Year-over-year growth 2022-2027 (%)
• Exhibit 98: Data Table on UK - Year-over-year growth 2022-2027 (%)
• 9.11 Japan - Market size and forecast 2022-2027
• Exhibit 99: Chart on Japan - Market size and forecast 2022-2027 ($ million)
• Exhibit 100: Data Table on Japan - Market size and forecast 2022-2027 ($ million)
• Exhibit 101: Chart on Japan - Year-over-year growth 2022-2027 (%)
• Exhibit 102: Data Table on Japan - Year-over-year growth 2022-2027 (%)
• 9.12 Market opportunity By Geographical Landscape
• Exhibit 103: Market opportunity By Geographical Landscape ($ million)
• Exhibit 104: Data Tables on Market opportunity By Geographical Landscape ($ million)

10 Drivers, Challenges, and Trends

• 10.1 Market drivers
• 10.2 Market challenges
• 10.3 Impact of drivers and challenges
• Exhibit 105: Impact of drivers and challenges in 2022 and 2027
• 10.4 Market trends

11 Vendor Landscape

• 11.1 Overview
• 11.2 Vendor landscape
• Exhibit 106: Overview on Criticality of inputs and Factors of differentiation
• 11.3 Landscape disruption
• Exhibit 107: Overview on factors of disruption
• 11.4 Industry risks
• Exhibit 108: Impact of key risks on business

12 Vendor Analysis

• 12.1 Vendors covered
• Exhibit 109: Vendors covered
• 12.2 Market positioning of vendors
• Exhibit 110: Matrix on vendor position and classification
• 12.3 Apotex Inc.
• Exhibit 111: Apotex Inc. - Overview
• Exhibit 112: Apotex Inc. - Product / Service
• Exhibit 113: Apotex Inc. - Key offerings
• 12.4 Aurobindo Pharma Ltd.
• Exhibit 114: Aurobindo Pharma Ltd. - Overview
• Exhibit 115: Aurobindo Pharma Ltd. - Product / Service
• Exhibit 116: Aurobindo Pharma Ltd. - Key offerings
• 12.5 Bristol Myers Squibb Co.
• Exhibit 117: Bristol Myers Squibb Co. - Overview
• Exhibit 118: Bristol Myers Squibb Co. - Product / Service
• Exhibit 119: Bristol Myers Squibb Co. - Key news
• Exhibit 120: Bristol Myers Squibb Co. - Key offerings
• 12.6 Cipla Ltd.
• Exhibit 121: Cipla Ltd. - Overview
• Exhibit 122: Cipla Ltd. - Business segments
• Exhibit 123: Cipla Ltd. - Key news
• Exhibit 124: Cipla Ltd. - Key offerings
• Exhibit 125: Cipla Ltd. - Segment focus
• 12.7 Debiopharm International SA
• Exhibit 126: Debiopharm International SA - Overview
• Exhibit 127: Debiopharm International SA - Product / Service
• Exhibit 128: Debiopharm International SA - Key news
• Exhibit 129: Debiopharm International SA - Key offerings
• 12.8 Entasis Therapeutics
• Exhibit 130: Entasis Therapeutics - Overview
• Exhibit 131: Entasis Therapeutics - Product / Service
• Exhibit 132: Entasis Therapeutics - Key offerings
• 12.9 F. Hoffmann La Roche Ltd.
• Exhibit 133: F. Hoffmann La Roche Ltd. - Overview
• Exhibit 134: F. Hoffmann La Roche Ltd. - Business segments
• Exhibit 135: F. Hoffmann La Roche Ltd. - Key news
• Exhibit 136: F. Hoffmann La Roche Ltd. - Key offerings
• Exhibit 137: F. Hoffmann La Roche Ltd. - Segment focus
• 12.10 GlaxoSmithKline Plc
• Exhibit 138: GlaxoSmithKline Plc - Overview
• Exhibit 139: GlaxoSmithKline Plc - Business segments
• Exhibit 140: GlaxoSmithKline Plc - Key news
• Exhibit 141: GlaxoSmithKline Plc - Key offerings
• Exhibit 142: GlaxoSmithKline Plc - Segment focus
• 12.11 Hikma Pharmaceuticals Plc
• Exhibit 143: Hikma Pharmaceuticals Plc - Overview
• Exhibit 144: Hikma Pharmaceuticals Plc - Business segments
• Exhibit 145: Hikma Pharmaceuticals Plc - Key offerings
• Exhibit 146: Hikma Pharmaceuticals Plc - Segment focus
• 12.12 Lupin Ltd.
• Exhibit 147: Lupin Ltd. - Overview
• Exhibit 148: Lupin Ltd. - Product / Service
• Exhibit 149: Lupin Ltd. - Key news
• Exhibit 150: Lupin Ltd. - Key offerings
• 12.13 Mayne Pharma Group Ltd.
• Exhibit 151: Mayne Pharma Group Ltd. - Overview
• Exhibit 152: Mayne Pharma Group Ltd. - Business segments
• Exhibit 153: Mayne Pharma Group Ltd. - Key news
• Exhibit 154: Mayne Pharma Group Ltd. - Key offerings
• Exhibit 155: Mayne Pharma Group Ltd. - Segment focus
• 12.14 Pfizer Inc.
• Exhibit 156: Pfizer Inc. - Overview
• Exhibit 157: Pfizer Inc. - Product / Service
• Exhibit 158: Pfizer Inc. - Key news
• Exhibit 159: Pfizer Inc. - Key offerings
• 12.15 Sun Pharmaceutical Industries Ltd.
• Exhibit 160: Sun Pharmaceutical Industries Ltd. - Overview
• Exhibit 161: Sun Pharmaceutical Industries Ltd. - Product / Service
• Exhibit 162: Sun Pharmaceutical Industries Ltd. - Key offerings
• 12.16 Teva Pharmaceutical Industries Ltd.
• Exhibit 163: Teva Pharmaceutical Industries Ltd. - Overview
• Exhibit 164: Teva Pharmaceutical Industries Ltd. - Business segments
• Exhibit 165: Teva Pharmaceutical Industries Ltd. - Key news
• Exhibit 166: Teva Pharmaceutical Industries Ltd. - Key offerings
• Exhibit 167: Teva Pharmaceutical Industries Ltd. - Segment focus
• 12.17 Therapyx Inc.
• Exhibit 168: Therapyx Inc. - Overview
• Exhibit 169: Therapyx Inc. - Product / Service
• Exhibit 170: Therapyx Inc. - Key offerings

13 Appendix

• 13.1 Scope of the report
• 13.2 Inclusions and exclusions checklist
• Exhibit 171: Inclusions checklist
• Exhibit 172: Exclusions checklist
• 13.3 Currency conversion rates for US$
• Exhibit 173: Currency conversion rates for US$
• 13.4 Research methodology
• Exhibit 174: Research methodology
• Exhibit 175: Validation techniques employed for market sizing
• Exhibit 176: Information sources
• 13.5 List of abbreviations
• Exhibit 177: List of abbreviations